Ranking Invest

Celldex Therapeutics, Inc.

Segmento: Healthcare Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Indicadores Básicos

Valor de Mercado

$ 1.60 Bi

IVR

0.14

IVR2

-0.31

Índices de Previsibilidade

Faturamento

0.85

Lucro

0.18

Margem

0.80

Índices de Tendência

Faturamento

2.63

Lucro

-8.86

Margem

2.47

Índices de Endividamento

DIV/PAT

-0.02

DIV/L4T

0.08

Dívida Líquida

-$ 13.71 Mi

Patrimônio Líquido

$ 702.98 Mi

L4T

-$ 178.85 Mi

MM4T

-3625.77%

Dívidas
Dividendos
Cotação: $24.02

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre